THERAPY DOSSIER · th-277f7df080b0

FG-4592 (roxadustat)

Drug · HIF prolyl-hydroxylase (PHD) inhibitor; stimulates erythropoiesis.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: HIF prolyl-hydroxylase (PHD) inhibitor; stimulates erythropoiesis.
Target: CHEMBL3831261 (HIF-PHD)
Injury models: Wound
Reported indication: Not recorded
First approval: 2021
Development stage: Not recorded
ChEMBL record: CHEMBL2338329 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Evrenzo; FG-4592; ASP-1517
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02652819 ↗PHASE3completed

FG-4592 (Roxadustat) for Anemia in Non-Dialysis CKD

Anemia

Enrolment: 154 · Results not recorded

NCT04925661 ↗PHASE1completed

HEC53856 vs Roxadustat in Non-dialysis Renal Anemia

Renal Anemia

Enrolment: 40 · Results not recorded

NCT04502537 ↗NAunknown

Roxadustat for Anemia in Chronic Kidney Disease (Cohort)

Anemia of Chronic Kidney Disease

Enrolment: 200 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29742498 ↗2018Reported benefit

FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1alpha Stabilization.

MouseWoundBALB/c (from MeSH indexing)male (from MeSH indexing)

Model: Cutaneous excisional skin wound

Acute hypoxia switched epidermal stem cells from quiescence to an activated state with higher viability and motility, mediated by HIF-1 signalling. Exogenous FG-4592 accelerated wound healing, shortened healing time and induced epidermal hyperplasia in vivo.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…